



Faculty Scholarship

2018

The antioxidant xanthorrhizol prevents amyloid- β -induced oxidative modification and inactivation of neprilysin

Chol Seung Lim

Jung-Soo Han

Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications



Part of the [Biology Commons](#), and the [Diseases Commons](#)

Research Article

The antioxidant xanthorrhizol prevents amyloid- β -induced oxidative modification and inactivation of neprilysin

Chol Seung Lim¹ and Jung-Soo Han²¹Center for Neurodegenerative Diseases, Blanchette Rockefeller Neurosciences Institute, West Virginia University, Morgantown, WV 26505, U.S.A.; ²Department of Biological Sciences, Konkuk University, Seoul 05029, South Korea**Correspondence:** Chol Seung Lim (clim@hsc.wvu.edu)

Activity of neprilysin (NEP), the major protease which cleaves amyloid- β peptide ($A\beta$), is reportedly reduced in the brains of patients with Alzheimer's disease (AD). Accumulation of $A\beta$ generates reactive oxygen species (ROS) such as 4-hydroxynonenal (HNE), and then reduces activities of $A\beta$ -degrading enzymes including NEP. Xanthorrhizol (Xan), a natural sesquiterpenoid, has been reported to possess antioxidant and anti-inflammatory properties. The present study examined the effects of Xan on HNE- or oligomeric $A\beta_{42}$ -induced oxidative modification of NEP protein. Xan was added to the HNE- or oligomeric $A\beta_{42}$ -treated SK-N-SH human neuroblastoma cells and then levels, oxidative modification and enzymatic activities of NEP protein were measured. Increased HNE levels on NEP proteins and reduced enzymatic activities of NEP were observed in the HNE- or oligomeric $A\beta_{42}$ -treated cells. Xan reduced HNE levels on NEP proteins and preserved enzymatic activities of NEP in HNE- or oligomeric $A\beta_{42}$ -treated cells. Xan reduced $A\beta_{42}$ accumulation and protected neurones against oligomeric $A\beta_{42}$ -induced neurotoxicity through preservation of NEP activities. These findings indicate that Xan possesses therapeutic potential for the treatment of neurodegenerative diseases, including AD, and suggest a potential mechanism for the neuroprotective effects of antioxidants for the prevention of AD.

Introduction

Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder characterized by cognitive decline [1,2]. AD is also characterized morphologically by extensive amyloid deposition, neurofibrillary tangles, and neuroinflammation leading to synaptic and neuronal loss [3,4]. Oligomeric forms of amyloid- β peptide ($A\beta$) aggregate and form senile plaques in the brains of patients with AD [5,6]. Abnormal accumulation of $A\beta$ is toxic to neurones [7,8]. Hence, treatments that prevent $A\beta$ accumulation could slow the neurodegeneration and cognitive decline in AD.

Increasing evidence has shown that $A\beta$ accumulation enhances its production and decreases its degradation through the actions of several $A\beta$ -degrading enzymes, including neprilysin (NEP), insulin-degrading enzyme, and endothelin-converting enzyme [9-12]. NEP, a predominant $A\beta$ protease, cleaves both monomeric and oligomeric forms of $A\beta$ in the brain [13-15]. NEP protein levels are reduced in the hippocampus and cortex of aged mice [16,17], and NEP is selectively down-regulated in areas of the AD brain with high levels of amyloid plaques [18,19]. Conversely, overexpression of NEP reduces $A\beta$ levels in a dose-dependent manner [20,21], and protects neurones from $A\beta$ -induced toxicity *in vitro* [22]. These results imply an inverse correlation between NEP activity and $A\beta$ levels, supporting the hypothesis that a reduction in NEP expression or its activity induces $A\beta$ deposition, and the subsequent neuronal dysfunction occurs in AD.

Received: 18 July 2017
Revised: 05 January 2018
Accepted: 09 January 2018Accepted Manuscript Online:
12 January 2018
Version of Record published:
2 February 2018




Figure 1. Xan prevents HNE-induced NEP modification

HNE-treated (10 μ M) SK-N-SH cells were incubated with Xan (1, 10 μ M) or NAC (10, 100 μ M) and then immunoblot and immunoprecipitation was followed. **(A)** A representative NEP immunoblot (top). Any treatment did not change total protein levels of NEP (bottom). **(B)** Effects of Xan or NAC on the HNE-induced modification of NEP. A representative HNE immunoblot (top). Xan reduced HNE-induced increases in HNE levels on NEP (bottom). **(C)** Untreated cells (a, b, c, d), cells with HNE only (e, f, g, h), cells with HNE and 10 μ M Xan (HNE + Xan; i, j, k, l), and cells with HNE and 100 μ M NAC (HNE + NAC; m, n, o, p) were immunostained with anti-NEP (green) or anti-HNE (red) antibodies. The nuclei were also stained with DAPI (blue). Cellular localization was determined by confocal overlay imaging. Evidently, Xan reduced HNE-positive signals in HNE-treated cells. Scale bar: 10 μ m; mean \pm S.E.M. from three independent experiments; *** P <0.001 compared with untreated controls; # P <0.05, ## P <0.01 compared with HNE-treated cells.

Oxidative stress has long been recognized as an important factor in the early development of AD [23-25]. $A\beta$ induces high levels of reactive oxygen species (ROS) [26]. Specifically, elevated levels of 4-hydroxynonenal (HNE), an α,β -unsaturated hydroxyalkenal that is produced by lipid peroxidation in $A\beta$ deposits could interact with, modify, and inactivate a variety of cellular proteins and enzymes [27,28]. It has been reported that NEP is modified by HNE and catalytic activity of HNE-modified NEP is decreased in AD brains and in HNE- or $A\beta$ -treated cells [29,30]. Therefore, it is expected that prevention of NEP oxidative modification may increase NEP activity and increased NEP activity may reduce $A\beta$ accumulation, which in turn results in protection of neurones against $A\beta$ -induced neurotoxicity.

Antioxidants have been reported as promising treatments for protecting neurones against oxidative stress [31,32]. Xanthorrhizol (Xan), isolated from *Curcuma xanthorrhiza* RoxB, has been reported to possess antibacterial and




Figure 2. Xan inhibits oligomeric A β_{42} -induced NEP modification in SK-N-SH cells

A β_{42} -treated (1 μ M) SK-N-SH cells were incubated with Xan (1, 10 μ M) or NAC (10, 100 μ M) and then immunoblotting and co-immunoprecipitation followed. **(A)** A representative NEP immunoblot (top). Any treatment did not change total protein levels of NEP (bottom). **(B)** Effects of Xan or NAC on the A β_{42} -induced modification of NEP. A representative immunoblot for HNE (top). Xan reduced A β_{42} -induced increases in HNE levels on NEP (bottom). **(C)** Untreated cells (a, b, c, d), cells with 1 μ M oligomeric A β_{42} only (e, f, g, h), cells with A β_{42} and 10 μ M Xan (A β + Xan; i, j, k, l), and cells with A β_{42} and 100 μ M NAC (A β + NAC; m, n, o, p) were immunostained with anti-NEP (green) or anti-HNE (red) antibodies. The nuclei were also stained with DAPI (blue). Cellular localization was determined by confocal overlay imaging. Evidently, Xan reduced HNE-positive signals in A β_{42} -treated cells. Scale bar: 10 μ m; mean \pm S.E.M. from three independent experiments; *** P <0.001 compared with untreated controls; # P <0.05, ## P <0.01 compared with A β_{42} -treated cells.

anti-inflammatory activity [33]. It is also reported that Xan has antioxidant properties, i.e. it directly scavenges hydrogen peroxide, it prevents ROS production and ROS-induced cell death, and it inhibits oxidative damage by reducing lipid peroxidation of cellular proteins [34]. Therefore, the present study examined effects of Xan on the oxidative NEP modification and NEP activities in HNE- or oligomeric A β_{42} -treated neuroblastoma cells, along with N-acetyl-L-cysteine (NAC) that has been reported to reduce A β_{42} -mediated oxidative modification [35].

Materials and methods

Cell culture and treatment

Human neuroblastoma SK-N-SH cells were obtained from the American Type Culture Collection (ATCC, HTB-11, Manassas, VA) and maintained in essential medium supplemented with 1 μ M non-essential amino acids, 100 UI/ml penicillin, 100 μ g/ml streptomycin, and 10% (v/v) FBS (all culture materials from Invitrogen, Carlsbad, CA) in a humidified atmosphere with 5% CO $_2$ at 37°C. Cells were subcultured twice per week and had undergone four to eight passages prior to the experiments.

A combination of HNE (Cayman Chemical, Ann Arbor, MI), Xan (Enzo Life Sciences, Farmingdale, NY), NAC (Sigma–Aldrich, St. Louis, MO), oligomeric A β_{42} (AnaSpec, Fremont, CA), or thiorphan (TP, Cayman Chemical), a specific NEP inhibitor, was added to the cultured cells according to experimental design. Xan and NAC were dissolved and diluted in Dulbecco's PBS (DPBS, pH 7.4). HNE and TP were freshly prepared in DMSO and diluted in PBS prior to the experiment. To induce oxidative modification of NEP, cells were kept in 2% serum-reduced medium for 16 h, and HNE (10 μ M) or oligomeric A β_{42} (1 μ M) were then added to the cultured cells for 12 h. The same volume PBS was added to the cultures to serve as untreated controls.

Preparation of A β_{42}

Monomeric and oligomeric A β_{42} were prepared as described previously [36], from aliquots of the same batch of A β_{42} . For oligomeric A β_{42} , lyophilized A β_{42} aliquots (0.3 mg) were dissolved in 0.2 ml of 1,1,1,3,3,3-Hexafluoro-2-propanol (HFP, Sigma–Aldrich) and then added to 0.7 ml H₂O. Samples were loosely capped and stirred on a magnetic stirrer under a fume hood for 48 h, and used within 36 h. Monomeric A β_{42} was prepared immediately before use by rapidly evaporating the HFP via gentle bubbling of nitrogen gas into the solution. The quality of A β_{42} preparations was checked by immunoblot with anti-A-11 (1:1000, Invitrogen) and anti-6E10 (1:1000, Covance, Princeton, NJ) antibodies.

Immunoprecipitation and immunoblot analysis

Cultured cells were lysed in cold lysis buffer (10 mM Tris/HCl, pH 7.4, 5 mM EDTA, 1% Triton X-100, 10% glycerol, 1 mM CaCl₂, 1 mM MgCl₂, and 1 \times complete protease inhibitor cocktail (Thermo Scientific, Waltham, MA)) for 1 h at 4°C. Total lysates (1 mg) were immunoprecipitated with an anti-NEP antibody (1 μ g/ml, Abcam, Cambridge, MA) at 4°C overnight, and protein/antibody immunocomplexes were purified with protein A-magnetic beads and a magnetic separator (both from Millipore, Temecula, CA). After washing, immunocomplexes were separated by SDS-PAGE using 10% gels (Invitrogen), transferred on to nitrocellulose membranes, and incubated with the primary rabbit polyclonal anti-HNE or rabbit polyclonal anti-NEP (both from Millipore) antibodies at room temperature overnight. After incubation with the secondary horseradish peroxidase (HRP)-conjugated goat anti-rabbit or mouse IgG (1:10000; Jackson ImmunoResearch Lab, West Grove, PA) antibodies, the membranes were developed with ECL and exposed to X-ray film (Thermo Scientific). As a control, membranes were stripped and re-probed with the primary mouse anti-NEP (1:1000, Abcam) or mouse anti- β -actin (1:4000, Sigma–Aldrich) antibodies followed by the secondary HRP-conjugated goat anti-mouse IgG (1:10000, Jackson ImmunoResearch Lab) antibody. Immunoreactivity was assessed by densitometric analysis of films using an HP Scanjet densitometer (Hewlett-Packard, Corvallis, OR) and ImageJ image analysis software (1.47v, NIH, Bethesda, MD) as described previously [37].

Immunocytochemistry

Cells grown on 2% gelatin (Sigma–Aldrich) coated coverslips (Carolina Biological Supply Company, Burlington, NC) were fixed with 4% paraformaldehyde at room temperature for 20 min and permeabilized with 0.2% Triton X-100 in 1 \times PBS (pH 7.4). After pre-blocking for 1 h at room temperature with 1% normal goat serum/1 \times PBS, cells were incubated overnight at 4°C in a humidified chamber with the primary mouse anti-NEP (1:100, Abcam) or rabbit anti-HNE (1:200, Millipore) antibodies. At the end of the incubation period, the cells were rinsed three times with 1 \times PBS containing 0.05% Tween-20 (PBS-T) and then incubated with the secondary Alexa 488-conjugated goat anti-mouse or Alexa 568-conjugated goat anti-rabbit IgG (1:500, Invitrogen) for 60 min at room temperature. All primary and secondary antibodies were diluted in PBS-T with 2% normal goat serum. After rinsing with 1 \times PBS, the coverslips were mounted using ProLong Gold antifade reagent with DAPI (Invitrogen), and viewed and photographed on a Zeiss LSM 710 laser scanning confocal microscope (Carl Zeiss, Thornwood, NY). Immunofluorescence staining was repeated at least three times.

Fluorometric NEP activity assay in cell lysates and intact cells

To determine NEP activity in whole cell lysates, cells were incubated with HNE (10 μ M) or oligomeric A β_{42} (1 μ M) without or with Xan (1, 10 μ M) or NAC (10, 100 μ M) for 12 h, collected, lysed in 1 \times PBS (pH 7.4) with 0.1% Triton X-100, and the lysates were placed on ice for 30 min. NEP activity in cell lysates was analyzed using a synthetic NEP fluorogenic peptide substrate (Mca-R-P-P-G-F-S-A-F-K[Dnp]-OH; R&D Systems, Inc., Minneapolis, MN) in the presence/absence of 500 nM TP. Samples were dissolved in 50 mM HEPES buffer (pH 7.5) and pre-incubated with TP or 1 \times PBS for 20 min prior to adding the NEP fluorogenic peptide substrate (dissolved in HEPES). Fluorescence was read at 320 nm excitation and 405 nm emission on a fluorescent microplate reader (BioTek, Winooski, VT).




Figure 3. Xan prevents HNE- and oligomeric Aβ₄₂-induced reduction in NEP activity in SK-N-SH cells

HNE-treated (10 μM) SK-N-SH cells were incubated with Xan (1, 10 μM) or NAC (10, 100 μM) and then NEP activities of whole cell lysates (A) and intact cells (B) were measured, using a fluorometric peptide substrate. Xan and NAC treatments prevented the HNE-induced reduction in NEP activity. Aβ₄₂-treated (1 μM) SK-N-SH cells were incubated with Xan (1, 10 μM) or NAC (10, 100 μM) and then NEP activities of whole cell lysates (C) and intact cells (D) were measured. Xan and NAC prevented the oligomeric Aβ₄₂-induced reduction in NEP activity. Average NEP activity was expressed as a percentage of the untreated control. Mean ± S.E.M. for three independent experiments; **P*<0.05, ***P*<0.01 compared with untreated controls; #*P*<0.05, ##*P*<0.01 compared with HNE- or Aβ₄₂-treated cells.

The activity of membrane-bound NEP in intact cells was measured as previously described [36]. Briefly, after treatment like above, intact cells were harvested, washed with 1× PBS (pH 7.4), and incubated with 1 mM glutaryl-Ala-Ala-Phe-4-methoxy-2-naphthylamide (Sigma-Aldrich) as the NEP substrate. The substrate solution was collected and incubated with leucine aminopeptidase (50 μg/ml, Sigma-Aldrich, St. Louis, MO, U.S.A.) in the presence/absence of 500 nM TP for 30 min at 37°C, and the released free 4-methoxy-2-naphthylamide was fluorometrically measured at an emission wavelength of 425 nm using a microplate reader (BioTek).

FRET assay was performed for kinetic analyses of NEP activity. Cell lysates prepared by the method described above were incubated with increasing concentrations of NEP fluorogenic peptide substrate (0–20 μM) at room temperature. Fluorescence was measured over a 1-h period. NEP activity was determined as the difference in fluorescence in the presence/absence of 500 nM TP. Kinetic isotherms (*V*_{max} and *K*_m values) for NEP activity were determined by non-linear least squares fitting to the Michaelis–Menten equation using GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA).




Figure 4. Xan enhances V_{max} and K_m values of NEP enzymatic activity in SK-N-SH cells

(A) NEP activity in untreated cells, cells with HNE (10 μ M), cells with HNE and Xan (10 μ M), and cells with HNE and NAC (100 μ M) was determined using FRET assay. (B) NEP activity in the untreated cells, the cells with oligomeric A β_{42} (1 μ M), the cells with A β_{42} and Xan (10 μ M), and cells with A β_{42} and NAC (100 μ M) was determined using FRET assay. The dependence of the mean NEP activity on increasing substrate concentration (0–20 μ M) in SK-N-SH lysates was measured using FRET assay, and then the V_{max} and K_m values (C) were calculated. The NEP K_m values were decreased by HNE or oligomeric A β_{42} treatments and preserved by Xan or NAC pre-treatment. Mean \pm S.E.M. from three independent experiments.

***In vitro* A β cleavage assay**

SK-N-SH cells were incubated with Xan (1, 10 μ M) or NAC (10, 100 μ M), in the presence/absence of 500 nM TP for 1 h. NEP proteins were isolated by immunoprecipitation from cells. For the *in vitro* cleavage assay, isolated NEP proteins were incubated with the same amount of 2.5 μ M monomeric or oligomeric A β_{42} in 20 mM HEPES, pH 7.4, 10 mM KCl, and 10 mM MgCl₂ for an additional 4 h at 30°C. The reaction mixture was separated on SDS/PAGE (10–20% gel) (Invitrogen), blotted, and probed with anti-6E10 antibody (1:1000, Covance) as described in ‘Immunoprecipitation and immunoblot analysis’ section. Cleavage of A β_{42} was discerned by the disappearance of protein bands corresponding to intact monomeric and oligomeric A β_{42} . The densities of the remaining A β_{42} bands were quantitated using an HP Scanjet densitometer and ImageJ image analysis software, and plotted using GraphPad Prism 6 software.

Cell toxicity assay

Cells were cultured in 48- or 96-well plates at a density of ~3000–5000 cells/well in complete growth medium for 24 h. Growth medium was replaced with fresh culture medium (~100–200 μ l/well) containing 2.0% FBS and 1 μ M oligomeric A β_{42} for 24 h. Another batch of cells were co-treated with Xan or NAC in the presence/absence of 500 nM TP. After 24 h, a cell viability assay was performed as described previously [34,36] using the Cell Counting Kit-8 (Dojindo, Rockville, MD). Briefly, ~10–20 μ l of CCK-8 solution was added to all wells, and the plates were incubated for 4 h at 37°C in 5% CO₂. The culture medium was collected and detected with a microplate reader at a wavelength of 450 nm. The difference in optical density (OD) relative to untreated controls was taken as a measure of cell viability, and the percentage of viable cells was calculated by comparing the OD at 450 nm for the A β_{42} -treated and control wells.

Statistical analysis

Data were expressed with a percentage of untreated controls. All data are presented as mean \pm S.E.M. from three or more independent experiments, unless otherwise indicated. Differences between untreated cells and HNE- or oligomeric A β_{42} -treated cells were examined using a *t* test. One-way ANOVA was conducted to see the effects of Xan and NAC on conditions with these experimental treatments. Subsequent *post hoc* test (Tukey's multiple comparison) was followed. *P*-values less than 0.05 were considered significant, unless specified otherwise.

Results

Xan prevented HNE-induced NEP modification

Effects of Xan and NAC on the HNE-treated SK-N-SH cells were examined by measurements of oxidative modification of NEP (Figure 1). Any treatment did not change total NEP levels (Figure 1A). However, HNE treatment markedly increased HNE levels on NEP proteins ($t(10) = 9.73$, $P < 0.001$; Figure 1B), which was effectively reduced by 1 μ M Xan treatment by 38%; 10 μ M Xan reduced 59% HNE levels on NEP proteins in the HNE-treated cells ($F(2,15) = 11.74$, $P < 0.01$); 10 and 100 μ M NAC also reduced 36 and 49% HNE levels on NEP proteins, respectively, in the HNE-treated cells ($F(2,15) = 11.17$, $P < 0.01$; Figure 1B).

Furthermore, we observed that HNE-induced HNE increases on NEP proteins using double immunofluorescence staining. As shown in Figure 1C, HNE-positive signals were undetectable in untreated controls, but were abundant and co-localized with NEP-positive signals in the HNE-treated cells. Both 10 μ M Xan and 100 μ M NAC treatments reduced the HNE-positive signals in the HNE-treated cells.

Xan prevented oligomeric A β_{42} -induced HNE modification of NEP

Effects of Xan and NAC on the oligomeric A β_{42} -treated SK-N-SH cells was examined by measurements of oxidative modification of NEP (Figure 2). Any treatment did not change total NEP levels (Figure 2A). However, oligomeric A β_{42} treatments markedly increased HNE levels on NEP proteins ($t(10) = 9.04$, $P < 0.001$; Figure 2B); 1 and 10 μ M Xan treatments decreased 47 and 75% HNE levels on NEP proteins in the oligomeric A β_{42} -treated cells, respectively ($F(2,15) = 11.83$, $P < 0.01$); 10 and 100 μ M NAC treatments also reduced 42 and 70% HNE levels on NEP proteins in the oligomeric A β_{42} -treated cells, respectively ($F(2,15) = 8.57$, $P < 0.01$; Figure 2B).

Furthermore, we observed oligomeric A β_{42} -induced HNE increases on NEP proteins using double immunofluorescence staining. As shown in Figure 2C, HNE-positive signals were undetectable in untreated controls, but were abundant and co-localized with NEP-positive signals in the oligomeric A β_{42} -treated cells. Both 10 μ M Xan and 100 μ M NAC treatments reduced the HNE-positive signals in the oligomeric A β_{42} -treated cells.

Xan protected HNE- or oligomeric A β_{42} -induced NEP inactivation

HNE treatment induces NEP modification, resulting in inactivation of NEP protein. Therefore, it is predicted that prevention of either HNE- or oligomeric A β_{42} -induced NEP modification would preserve NEP activity. The present experiment examined the changes in NEP activity in HNE- or oligomeric A β_{42} -treated SK-N-SH lysates and intact cells, using a fluorometric peptide substrate. Exogenous treatment of 10 μ M HNE into cells led to a significant loss of NEP activity, by 51% in whole cell lysates ($t(20) = 5.45$, $P < 0.05$; Figure 3A) and by 61% in intact cells ($t(20) = 7.16$, $P < 0.01$; Figure 3B). However, 1 and 10 μ M Xan treatments increased 35 and 49% NEP activities in the HNE-treated cell lysates, respectively ($F(2,30) = 9.90$, $P < 0.05$). In addition, 1 and 10 μ M Xan treatments increased 41 and 60% NEP activities in the HNE-treated intact cells, respectively ($F(2,30) = 16.26$, $P < 0.01$). Similar patterns were observed in the NAC experiments: 10 and 100 μ M NAC treatments increased 37 and 52% NEP activities in the HNE-treated cell lysates, respectively, ($F(2,30) = 6.81$, $P < 0.05$; Figure 3A), and 35 and 59% NEP activities in the HNE-treated intact cells, respectively ($F(2,30) = 8.24$, $P < 0.01$; Figure 3B).

Since oligomeric A β_{42} increases endogenous generation of HNE and subsequently leads to HNE-induced modifications in NEP, we measured NEP activity in oligomeric A β_{42} -treated cells (Figure 3C,D). Similar to results of HNE-treated cells, oligomeric A β_{42} decreased 53% NEP activities in whole cell lysates ($t(18) = 5.86$, $P < 0.05$; Figure 3C) and 65% NEP activities in intact cells ($t(18) = 7.56$, $P < 0.01$; Figure 3D); 1 and 10 μ M Xan treatments recovered 32 and 52% NEP activities in the A β_{42} -treated whole cell lysates ($F(2,27) = 11.74$, $P < 0.05$); 36 and 59% in the A β_{42} -treated intact cells ($F(2,27) = 17.05$, $P < 0.01$); 10 and 100 μ M NAC treatments also recovered 23 and 40% NEP activities in the A β_{42} -treated whole cell lysates, respectively ($F(2,27) = 3.93$, $P < 0.05$); 15 and 57% in the A β_{42} -intact cells, respectively ($F(2,27) = 9.18$, $P < 0.01$).




Figure 5. Xan enhances NEP-mediated Aβ₄₂ degradation

NEP proteins were isolated from untreated cells, cells with Xan (1, 10 μM), cells with TP (500 nM) + Xan (10 μM), cells with NAC (10, 100 μM), and cells with TP + NAC (100 μM), using immunoprecipitation. These isolated NEP proteins were incubated with monomeric (A) and oligomeric (B) Aβ₄₂ (2.5 μM). The densities of the Aβ₄₂ bands were quantitated. Xan and NAC decreased monomeric and oligomeric Aβ₄₂ levels. However, TP, an NEP inhibitor, abolished the effects of Xan and NAC on the Aβ₄₂ degradation. Mean ± S.E.M. for three independent experiments; **P*<0.05; ***P*<0.01 compared with untreated cells; ##*P*<0.01 compared with Xan (10 μM)- or NAC (100 μM)-treated cells.

To further characterize the effect of Xan on NEP activation, we used a range of NEP substrate concentrations (0–20 μM) in SK-N-SH cells and then measured NEP activity using a FRET assay. The measurement of NEP activity was saturable and followed Michaelis–Menten kinetics in all cell samples (Figure 4). The *V*_{max} of NEP activity was decreased in the HNE- or oligomeric Aβ₄₂-treated cells; 1 μM Xan pre-treatment cells slightly normalized the *V*_{max} in the HNE- or oligomeric Aβ₄₂-treated cells, but it was not statistically significant, compared with the HNE- or oligomeric Aβ₄₂-treated cells; however, 10 μM Xan completely recovered the *V*_{max} (Figure 4A,B); 100 μM NAC treatment had a similar effect on the recovery of the *V*_{max} of NEP activity (Figure 4A,B). Lineweaver–Burk double-reciprocal plots of the reaction velocities and substrate concentrations permitted calculation of the Michaelis constant (*K*_m) for the enzyme in all samples. The NEP *K*_m values were decreased by HNE or oligomeric Aβ₄₂ treatment and recovered by Xan or NAC pre-treatment (Figure 4C).

Xan enhanced the ability of NEP to degrade Aβ₄₂ peptide and the resistance of SK-N-SH cells to Aβ₄₂-induced neurotoxicity through NEP activation

The present experiment examined the effect of Xan through NEP action on the degradation of Aβ₄₂; 1 and 10 μM Xan treatments decreased 54 and 72% monomeric Aβ₄₂ levels, respectively, compared with the untreated control (*F*(2,15) = 69.57, *P*<0.01). Similarly, 10 and 100 μM NAC treatments decreased 52 and 71% monomeric Aβ₄₂ levels, respectively, compared with the untreated control (*F*(2,15) = 74.81, *P*<0.01); 500 nM TP, an NEP inhibitor, almost completely abolished the effect of Xan (*t*(10) = 9.739, *P*<0.01) and NAC (*t*(10) = 13.61, *P*<0.01) on Aβ₄₂ degradation (Figure 5A). Notably, 1 and 10 μM Xan treatments cleaved oligomeric Aβ₄₂ by approximately 46 and 63%, respectively, compared with the untreated control (*F*(2,15) = 57.96, *P*<0.01). And 10 and 100 μM NAC reduced 37 and 56% oligomeric Aβ₄₂ levels, respectively, compared with the untreated control (*F*(2,15) = 47.18, *P*<0.01); 500 nM TP completely abolished the effect of Xan or NAC on oligomeric Aβ₄₂ cleavage (Figure 5B).




Figure 6. Xan protects against A β_{42} -induced neuronal toxicity in SK-N-SH cells

The viabilities of untreated cells, cells with oligomeric A β_{42} (1 μ M), cells with oligomeric A β_{42} + Xan (1, 5, 10 μ M), cells with oligomeric A β_{42} + Xan (10 μ M) + TP (500 nM), cells with oligomeric A β_{42} + NAC (10, 50, 100 μ M), and cells with oligomeric A β_{42} + NAC (100 μ M) + TP, was determined. Viabilities of oligomeric A β_{42} -treated cells evidently were decreased compared with untreated cells (**). Xan and NAC increased cell viabilities of A β_{42} -treated cells in a dose-dependent manner, but these Xan and NAC effects was abolished by TP, an NEP inhibitor. Data are expressed as the percentage of untreated cells. Mean \pm S.E.M. of three independent experiments; $P < 0.01$ compared with untreated controls; # $P < 0.05$, ## $P < 0.01$ compared with A β_{42} -treated cells; \$\$ $P < 0.01$ compared with A β_{42} + Xan or A β_{42} + NAC-treated cells.

We examined the protective effects of Xan or NAC against oligomeric A β_{42} -induced neurotoxicity via their NEP action. Oligomeric A β_{42} -treated SK-N-SH cells were incubated with Xan or NAC in the presence/absence of TP. The viabilities of neuroblastoma cells were significantly decreased by the oligomeric A β_{42} treatment ($t(14) = 9.28$, $P < 0.01$). But Xan and NAC treatments increased the viabilities of the oligomeric A β_{42} -treated cells in a dose-dependent manner; 1, 5, and 10 μ M Xan increased 5, 30, and 40% viabilities, respectively ($F(3,28) = 11.94$, $P < 0.01$), and 10, 50, and 100 μ M NAC increased 5, 16, and 36% viabilities ($F(3,28) = 7.73$, $P < 0.01$). NEP inhibition by TP almost completely abolished the protective effect of Xan ($t(14) = 4.63$, $P < 0.01$) or NAC ($t(14) = 3.41$, $P < 0.01$) on cell viability (Figure 6).

Discussion

During ageing and in neurodegenerative diseases including AD, oxidative stress such as excess reactive HNE results in modification of membrane lipids, DNA, and cellular proteins, which in turn alter their function [2,24,25]. HNE-modified proteins are abundant in the brains of AD patients, suggesting a role of oxidative damage in AD pathogenesis [26,27,35,38]. For example, increased HNE levels on NEP proteins and decreased activities of HNE-modified NEP in A β deposits have been observed in the AD brain [30,35]. Experimental evidences have demonstrated that NEP, a major A β -degrading enzyme, is one of HNE-induced oxidized proteins [29,30]. Therefore, one of potential strategies for preventing AD is an administration of antioxidants that inhibit HNE-induced NEP modification and prevent the loss of NEP activity [32]. Hence, the present study examined the effects of the antioxidants on HNE- or A β -induced NEP modification and activity, and subsequently demonstrated their protective effects through actions on NEP against A β_{42} -induced neurotoxicity.

Xan is the most active compound isolated from *C. xanthorrhiza* RoxB, possessing several biological activities including antioxidant and anti-inflammatory effects [31]. Specifically, our previous study showed that Xan has anti-inflammatory activity, i.e. it inhibits pro-inflammatory cytokines, such as interleukin-6 and tumor necrosis factor- α , and inhibits nitric oxide (NO) production in lipopolysaccharide-activated microglial cells [34]. In addition,

Xan reduces the expression of cyclooxygenase-2 and inducible nitric oxide synthase (iNOS), which results in reduction in NO in activated microglial cells [34]. Xan has potent neuroprotective effects against glutamate-induced neurotoxicity and ROS generation in hippocampal HT22 cells, and inhibits lipid peroxidation in rat brain homogenates with H₂O₂ treatments [34]. Therefore, it is expected that Xan, an antioxidant, could inhibit HNE-induced modification of the NEP protein. Both exogenous HNE treatments and the induction of endogenous HNE by oligomeric A β ₄₂ increased HNE levels on NEP proteins. These results are consistent with previous reports that A β increased the production of HNE and free radicals in neurones [35,39]. Importantly, Xan reduced HNE levels on NEP proteins in HNE- or A β ₄₂-treated cells. NAC as a positive control showed similar results.

A β peptide plays a pivotal role in the pathogenesis of AD [10,12]. A β - or oxidant-induced HNE modification reduces the activity of both endogenous and recombinant NEP protein [30,40], following a reduction in A β -degrading ability of NEP and A β accumulation [29,30]. It is also confirmed in our previous study that the activity of NEP was reduced in oligomeric A β ₄₂-treated cells [36]. Thus, reduction in NEP activity likely accelerates the development and progression of AD [29,40]. On the contrary, enhancement of A β -degrading enzyme activity would promote A β degradation [13,22]. In the present study, Xan and NAC prevented the inactivation of NEP by HNE or oligomeric A β ₄₂ treatment. V_{max} and K_m analyses revealed that NEP activity followed Michaelis–Menten kinetics, with a hyperbolic dependence of v (velocity) on substrate concentration. HNE or oligomeric A β ₄₂ decreased V_{max} and K_m of NEP activity, whereas Xan or NAC restored V_{max} and K_m of NEP activity in cells with HNE or oligomeric A β ₄₂ treatments. These results suggest that a reduction in NEP activity by HNE could be reversed by antioxidants. Furthermore, the present experiment demonstrated that Xan or NAC treatments degraded both monomeric and toxic oligomeric A β ₄₂ and protect neuronal cells against oligomeric A β ₄₂-induced toxicity via enhancing NEP activity.

Numerous studies have demonstrated that direct antioxidants, such as flavonoids, indirect antioxidants, such as NOS inhibitors, and metabolic antioxidants, such as NAC, can prevent neurodegeneration in AD [41,42]. The present results indicate that these actions are related to the protection of the A β -degrading enzyme NEP from oxidative modification and inactivation. Though NEP is a major physiological A β -degrading enzyme, several other enzymes such as angiotensin-converting enzyme also degrade A β peptides [9,14,15,20]. Future studies will examine roles of these A β -degrading enzymes in oxidative modification and A β -degrading activity, and effects of antioxidants on these enzymes.

However, amyloid plaque composed of A β is one of two major pathological features in AD. Even though if it is limited to the amyloid cascade hypothesis, aggregation of A β evokes oxidative damage, inflammation, and neurotoxicity. Oxidative damage contributes to inflammation in AD and A β -induced neurotoxicity is exacerbated under inflammation dysregulation [7, 23]. The present study proved only the possibility of Xan as an antioxidant treatment of AD. Because, as already reported, Xan has a variety of biological activities such as anti-inflammatory properties [31]. These properties and efficacies of Xan need to be studied using primary cultured neurones *in vitro* as well as *in vivo* in the brains of AD animal models with several pathological features of AD, with research to reveal its molecular and cellular mechanism.

Funding

This work was supported in part by the Institute's Internal Research Grant (to C.S.L.).

Competing interests

The authors declare that there are no competing interests associated with the manuscript.

Author contribution

C.S.L. and J.-S.H. conceived and designed the study. C.S.L. performed the experiments. C.S.L. and J.-S.H. wrote the manuscript.

Abbreviations

AD, Alzheimer's disease; A β , amyloid- β peptide; CCK-8, Cell Counting Kit-8; HFP, 1,1,1,3,3,3-Hexafluoro-2-propanol; HNE, 4-hydroxynonenal; HRP, horseradish peroxidase; NAC, N-acetyl-L-cysteine; NEP, neprilysin; ROS, reactive oxygen species; TP, thiorphan; Xan, xanthorrhizol.

References

- Selkoe, D.J. (2001) Alzheimer's disease: gene, protein, and therapy. *Physiol. Rev.* **81**, 741–766, <https://doi.org/10.1152/physrev.2001.81.2.741>
- Areosa, S.A. and Sherriff, F. (2003) Memantine for dementia. *Cochrane Database Syst. Rev.* **2003**, CD003154
- Selkoe, D.J. (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. *Behav. Brain Res.* **192**, 106–113, <https://doi.org/10.1016/j.bbr.2008.02.016>

- 4 Sperling, R.A., Dickerson, B.C., Pihlajamaki, M., Vannini, P., LaViolette, P.S., Vitolo, O.V. et al. (2010) Functional alterations in memory networks in early Alzheimer's disease. *Neuromolecular Med.* **12**, 27–43, <https://doi.org/10.1007/s12017-009-8109-7>
- 5 Wu, H.Y., Hudry, E., Hashimoto, T., Kuchibhotla, K., Rozkalne, A., Fan, Z. et al. (2010) Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. *J. Neurosci.* **30**, 2636–2649, <https://doi.org/10.1523/JNEUROSCI.4456-09.2010>
- 6 Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S. et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. *Science* **274**, 99–102, <https://doi.org/10.1126/science.274.5284.99>
- 7 Hardy, J. and Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* **297**, 353–356, <https://doi.org/10.1126/science.1072994>
- 8 Wang, D.S., Dickson, D.W. and Malter, J.S. (2006) Beta-amyloid degradation and Alzheimer's disease. *J. Biomed. Biotechnol.* **2006**, 58406, <https://doi.org/10.1155/JBB/2006/58406>
- 9 Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J.C. et al. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. *Science* **330**, 1774, <https://doi.org/10.1126/science.1197623>
- 10 Kowall, N.W., McKee, A.C., Yankner, B.A. and Beal, M.F. (1992) *In vivo* neurotoxicity of beta-amyloid [beta(1-40)] and the beta(25-35) fragment. *Neurobiol. Aging* **13**, 537–542, [https://doi.org/10.1016/0197-4580\(92\)90053-Z](https://doi.org/10.1016/0197-4580(92)90053-Z)
- 11 Jacobsen, J.S., Wu, C.C., Redwine, J.M., Comery, T.A., Arias, R., Bowlby, M. et al. (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 5161–5166, <https://doi.org/10.1073/pnas.0600948103>
- 12 Hardy, J. (1997) Amyloid, the presenilins and Alzheimer's disease. *Trends Neurosci.* **20**, 154–159, [https://doi.org/10.1016/S0166-2236\(96\)01030-2](https://doi.org/10.1016/S0166-2236(96)01030-2)
- 13 Eckman, E.A. and Eckman, C.B. (2005) Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. *Biochem. Soc. Trans.* **33**, 1101–1105
- 14 Miners, J.S., Baig, S., Palmer, J., Palmer, L.E., Kehoe, P.G. and Love, S. (2008) Abeta-degrading enzymes in Alzheimer's disease. *Brain Pathol.* **18**, 240–252, <https://doi.org/10.1111/j.1750-3639.2008.00132.x>
- 15 Wang, S., Wang, R., Chen, L., Bennett, D.A., Dickson, D.W. and Wang, D.S. (2010) Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. *J. Neurochem.* **115**, 47–57, <https://doi.org/10.1111/j.1471-4159.2010.06899.x>
- 16 Apelt, J., Ach, K. and Schliebs, R. (2003) Aging-related down-regulation of neprilysin, a putative beta-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques. *Neurosci. Lett.* **339**, 183–186, [https://doi.org/10.1016/S0304-3940\(03\)00030-2](https://doi.org/10.1016/S0304-3940(03)00030-2)
- 17 Iwata, N., Takaki, Y., Fukami, S., Tsubuki, S. and Saido, T.C. (2002) Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. *J. Neurosci. Res.* **70**, 493–500, <https://doi.org/10.1002/jnr.10390>
- 18 Reilly, C.E. (2001) Neprilysin content is reduced in Alzheimer brain areas. *J. Neurol.* **248**, 159–160, <https://doi.org/10.1007/s004150170259>
- 19 Yasojima, K., Akiyama, H., McGeer, E.G. and McGeer, P.L. (2001) Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. *Neurosci. Lett.* **297**, 97–100, [https://doi.org/10.1016/S0304-3940\(00\)01675-X](https://doi.org/10.1016/S0304-3940(00)01675-X)
- 20 Marr, R.A., Guan, H., Rockenstein, E., Kindy, M., Gage, F.H., Verma, I. et al. (2004) Neprilysin regulates amyloid beta peptide levels. *J. Mol. Neurosci.* **22**, 5–11, <https://doi.org/10.1385/JMN:22:1-2:5>
- 21 Iwata, N., Mizukami, H., Shirotani, K., Takaki, Y., Muramatsu, S., Lu, B. et al. (2004) Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. *J. Neurosci.* **24**, 991–998, <https://doi.org/10.1523/JNEUROSCI.4792-03.2004>
- 22 El-Amouri, S.S., Zhu, H., Yu, J., Gage, F.H., Verma, I.M. and Kindy, M.S. (2007) Neprilysin protects neurons against Abeta peptide toxicity. *Brain Res.* **1152**, 191–200, <https://doi.org/10.1016/j.brainres.2007.03.072>
- 23 McGeer, E.G. and McGeer, P.L. (2003) Inflammatory processes in Alzheimer's disease. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **27**, 741–749, [https://doi.org/10.1016/S0278-5846\(03\)00124-6](https://doi.org/10.1016/S0278-5846(03)00124-6)
- 24 Smith, M.A., Rottkamp, C.A., Nunomura, A., Raina, A.K. and Perry, G. (2000) Oxidative stress in Alzheimer's disease. *Biochim. Biophys. Acta* **1502**, 139–144, [https://doi.org/10.1016/S0925-4439\(00\)00040-5](https://doi.org/10.1016/S0925-4439(00)00040-5)
- 25 Varadarajan, S., Yatin, S., Aksenova, M. and Butterfield, D.A. (2000) Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. *J. Struct. Biol.* **130**, 184–208, <https://doi.org/10.1006/jsbi.2000.4274>
- 26 Smith, C.D., Carney, J.M., Starke-Reed, P.E., Oliver, C.N., Stadtman, E.R., Floyd, R.A. et al. (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. *Proc. Natl. Acad. Sci. U.S.A.* **88**, 10540–10543, <https://doi.org/10.1073/pnas.88.23.10540>
- 27 Sayre, L.M., Zelasko, D.A., Harris, P.L., Perry, G., Salomon, R.G. and Smith, M.A. (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. *J. Neurochem.* **68**, 2092–2097, <https://doi.org/10.1046/j.1471-4159.1997.68052092.x>
- 28 Ando, Y., Brannstrom, T., Uchida, K., Nyhlin, N., Näsman, B., Suhr, O. et al. (1998) Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. *J. Neurol. Sci.* **156**, 172–176, [https://doi.org/10.1016/S0022-510X\(98\)00042-2](https://doi.org/10.1016/S0022-510X(98)00042-2)
- 29 Wang, D.S., Iwata, N., Hama, E., Saido, T.C. and Dickson, D.W. (2003) Oxidized neprilysin in aging and Alzheimer's disease brains. *Biochem. Biophys. Res. Commun.* **310**, 236–241, <https://doi.org/10.1016/j.bbrc.2003.09.003>
- 30 Wang, R., Wang, S., Malter, J.S. and Wang, D.S. (2009) Effects of HNE-modification induced by Abeta on neprilysin expression and activity in SH-SY5Y cells. *J. Neurochem.* **108**, 1072–1082, <https://doi.org/10.1111/j.1471-4159.2008.05855.x>
- 31 Oon, S.F., Nallappan, M., Tee, T.T., Shohaimi, S., Kassim, N.K., Sa'ariwijaya, M.S. et al. (2015) Xanthorrhizol: a review of its pharmacological activities and anticancer properties. *Cancer Cell Int.* **15**, 100, <https://doi.org/10.1186/s12935-015-0255-4>
- 32 Grundman, M., Grundman, M. and Delaney, P. (2002) Antioxidant strategies for Alzheimer's disease. *Proc. Nutr. Soc.* **61**, 191–202, <https://doi.org/10.1079/PNS2002146>

- 33 Hwang, J.K., Shim, J.S., Baek, N.I. and Pyun, Y.R. (2000) Xanthorrhizol: a potential antibacterial agent from *Curcuma xanthorrhiza* against *Streptococcus mutans*. *Planta Med.* **66**, 196–197, <https://doi.org/10.1055/s-0029-1243135>
- 34 Lim, C.S., Jin, D.Q., Mok, H., Oh, S.J., Lee, J.U., Hwang, J.K. et al. (2005) Antioxidant and antiinflammatory activities of xanthorrhizol in hippocampal neurons and primary cultured microglia. *J. Neurosci. Res.* **82**, 831–838, <https://doi.org/10.1002/jnr.20692>
- 35 Wang, R., Malter, J.S. and Wang, D.S. (2010) N-acetylcysteine prevents 4-hydroxynonenal- and amyloid β -induced modification and inactivation of neprilysin in SH-SY5Y cells. *J. Alzheimers Dis.* **19**, 179–189, <https://doi.org/10.3233/JAD-2010-1226>
- 36 Lim, C.S. and Alkon, D.L. (2014) PKC ϵ promotes HuD-mediated neprilysin mRNA stability and enhances neprilysin-induced A β degradation in brain neurons. *PLoS ONE* **9**, e97756, <https://doi.org/10.1371/journal.pone.0097756>
- 37 Lim, C.S. and Alkon, D.L. (2012) Protein kinase C stimulates HuD-mediated mRNA stability and protein expression of neurotrophic factors and enhances dendritic maturation of hippocampal neurons in culture. *Hippocampus* **22**, 2303–2319, <https://doi.org/10.1002/hipo.22048>
- 38 Takeda, A., Smith, M.A., Avila, J., Nunomura, A., Siedlak, S.L., Zhu, X. et al. (2000) In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. *J. Neurochem.* **75**, 1234–1241, <https://doi.org/10.1046/j.1471-4159.2000.0751234.x>
- 39 Butterfield, D.A. and Lauderback, C.M. (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. *Free Radic. Biol. Med.* **32**, 1050–1060, [https://doi.org/10.1016/S0891-5849\(02\)00794-3](https://doi.org/10.1016/S0891-5849(02)00794-3)
- 40 Shinall, H., Song, E.S. and Hersh, L.B. (2005) Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral. *Biochemistry* **44**, 15345–15350, <https://doi.org/10.1021/bi050650l>
- 41 Prakash, A. and Kumar, A. (2009) Effect of N-acetyl cysteine against aluminium-induced cognitive dysfunction and oxidative damage in rats. *Basic Clin. Pharmacol. Toxicol.* **105**, 98–104, <https://doi.org/10.1111/j.1742-7843.2009.00404.x>
- 42 Behl, C. and Moosmann, B. (2002) Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. *Free Radic. Biol. Med.* **33**, 182–191, [https://doi.org/10.1016/S0891-5849\(02\)00883-3](https://doi.org/10.1016/S0891-5849(02)00883-3)